Literature DB >> 22473917

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Jasvinder A Singh1, Daniel E Furst, Aseem Bharat, Jeffrey R Curtis, Arthur F Kavanaugh, Joel M Kremer, Larry W Moreland, James O'Dell, Kevin L Winthrop, Timothy Beukelman, S Louis Bridges, W Winn Chatham, Harold E Paulus, Maria Suarez-Almazor, Claire Bombardier, Maxime Dougados, Dinesh Khanna, Charles M King, Amye L Leong, Eric L Matteson, John T Schousboe, Eileen Moynihan, Karen S Kolba, Archana Jain, Elizabeth R Volkmann, Harsh Agrawal, Sangmee Bae, Amy S Mudano, Nivedita M Patkar, Kenneth G Saag.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22473917      PMCID： PMC4081542          DOI： 10.1002/acr.21641

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  43 in total

1.  A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or computers.

Authors:  Theodore Pincus; Yusuf Yazici; Martin Bergman
Journal:  Best Pract Res Clin Rheumatol       Date:  2007-08       Impact factor: 4.098

2.  Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study.

Authors:  Aşkin Ateş; Gülay Kinikli; Murat Turgay; Gülay Akay; Güner Tokgöz
Journal:  Clin Rheumatol       Date:  2006-06-28       Impact factor: 2.980

3.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

4.  Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.

Authors:  E Berglin; T Johansson; U Sundin; E Jidell; G Wadell; G Hallmans; S Rantapää-Dahlqvist
Journal:  Ann Rheum Dis       Date:  2005-09-21       Impact factor: 19.103

5.  Infliximab treatment maintains employability in patients with early rheumatoid arthritis.

Authors:  Josef S Smolen; Chenglong Han; Désirée van der Heijde; Paul Emery; Joan M Bathon; Edward Keystone; Joachim R Kalden; Michael Schiff; Mohan Bala; Daniel Baker; John Han; Ravinder N Maini; E William St Clair
Journal:  Arthritis Rheum       Date:  2006-03

6.  Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis.

Authors:  Chenglong Han; Josef Smolen; Arthur Kavanaugh; E William St Clair; Daniel Baker; Mohan Bala
Journal:  Arthritis Rheum       Date:  2008-04-15

7.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

Authors:  Paul Emery; Ferdinand C Breedveld; Stephen Hall; Patrick Durez; David J Chang; Deborah Robertson; Amitabh Singh; Ronald D Pedersen; Andrew S Koenig; Bruce Freundlich
Journal:  Lancet       Date:  2008-07-16       Impact factor: 79.321

8.  Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.

Authors:  Miriam Kimel; Mary Cifaldi; Naijun Chen; Dennis Revicki
Journal:  J Rheumatol       Date:  2007-12-15       Impact factor: 4.666

9.  Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.

Authors:  Victoria Bejarano; Mark Quinn; Philip G Conaghan; Richard Reece; Anne-Maree Keenan; David Walker; Andrew Gough; Michael Green; Dennis McGonagle; Ade Adebajo; Stephen Jarrett; Sheelagh Doherty; Lesley Hordon; Richard Melsom; Kristina Unnebrink; Hartmut Kupper; Paul Emery
Journal:  Arthritis Rheum       Date:  2008-10-15

10.  Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.

Authors:  G Wells; J-C Becker; J Teng; M Dougados; M Schiff; J Smolen; D Aletaha; P L C M van Riel
Journal:  Ann Rheum Dis       Date:  2008-05-19       Impact factor: 19.103
View more
  518 in total

1.  Rheumatoid arthritis: Evidence-based rather than habit-based treatment options.

Authors:  Yusuf Yazici
Journal:  Nat Rev Rheumatol       Date:  2012-05-29       Impact factor: 20.543

2.  [Biologicals 2012].

Authors:  M Gaubitz
Journal:  Orthopade       Date:  2012-07       Impact factor: 1.087

3.  Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial.

Authors:  Daniel H Solomon; Elena Losina; Bing Lu; Agnes Zak; Cassandra Corrigan; Sara B Lee; Jenifer Agosti; Asaf Bitton; Leslie R Harrold; Theodore Pincus; Helga Radner; Zhi Yu; Josef S Smolen; Liana Fraenkel; Jeffrey N Katz
Journal:  Arthritis Rheumatol       Date:  2017-05-31       Impact factor: 10.995

Review 4.  Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases.

Authors:  Despoina Papadopoulou; Nikolaos V Sipsas
Journal:  Rheumatol Int       Date:  2013-12-10       Impact factor: 2.631

5.  Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?

Authors:  Di Liu; Na Yuan; Guimei Yu; Ge Song; Yan Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 6.  Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.

Authors:  Vivian P Bykerk; Elisabeth Lie; Susan J Bartlett; Rieke Alten; Annelies Boonen; Robin Christensen; Daniel E Furst; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; James E May; Pam Montie; Ana-Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia Woodworth; Clifton O Bingham; Ernest H Choy
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

7.  Assessing Unwanted Variations in Rheumatology Clinic Previsit Rooming.

Authors:  Edmond Ramly; Brad Stroik; Diane R Lauver; Heather M Johnson; Patrick McBride; Kristin Steffen Lewicki; Jon Arnason; Christie M Bartels
Journal:  J Clin Rheumatol       Date:  2019-04       Impact factor: 3.517

8.  Toward electronic health recording: evaluation of electronic patient reported outcome measures (e-PROMs) system for remote monitoring of early systemic lupus patients.

Authors:  Y El Miedany; M El Gaafary; Nadia El Aroussy; S Bahlas; M Hegazi; D Palmer; S Youssef
Journal:  Clin Rheumatol       Date:  2017-05-31       Impact factor: 2.980

9.  Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents.

Authors:  Josiane Bourré-Tessier; Mireia Arino-Torregrosa; Denis Choquette
Journal:  Clin Rheumatol       Date:  2014-02-21       Impact factor: 2.980

10.  Moderating effects of immunosuppressive medications and risk factors for post-operative joint infection following total joint arthroplasty in patients with rheumatoid arthritis or osteoarthritis.

Authors:  Elizabeth Salt; Amanda T Wiggins; Mary Kay Rayens; Brent J Morris; David Mannino; Andrew Hoellein; Ryan P Donegan; Leslie J Crofford
Journal:  Semin Arthritis Rheum       Date:  2016-08-24       Impact factor: 5.532
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.